IVVD Invivyd, Inc.

Nasdaq invivyd.com


$ 1.71 $ 0.00 (0 %)    

Wednesday, 15-Oct-2025 08:10:20 EDT
QQQ $ 604.16 $ 0.00 (0 %)
DIA $ 465.35 $ 0.00 (0 %)
SPY $ 667.48 $ 0.00 (0 %)
TLT $ 90.88 $ 0.00 (0 %)
GLD $ 385.67 $ 0.00 (0 %)
$ 1.63
$ 1.78
$ 1.68 x 3,044
$ 1.72 x 14
-- - --
$ 0.35 - $ 2.74
9,241,545
na
195.83M
$ 1.35
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 09-20-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-invivyd-raises-price-target-to-2

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:IVVD) with a Buy and raises the price target from $1 to $2.

 the-fda-clears-invivyds-investigational-new-drug-application-and-provided-feedback-to-advance-its-revolution--clinical-development-program-for-vyd2311-a-vaccine-alternative-monoclonal-antibody-candidate-to-prevent-covid-infection

The DECLARATION clinical trial is the company's Biologics License Application (BLA)-enabling, Phase 3 pivotal clinical tria...

 cantor-fitzgerald-initiates-coverage-on-invivyd-with-overweight-rating-announces-price-target-of-10

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Invivyd (NASDAQ:IVVD) with a Overweight rating and announces P...

 invivyd-filed-for-350m-mixed-shelf-offering

-SEC Filing

 steven-cohens-biotech-bets-are-getting-bolder--and-smaller

Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two clinical-stage companies, s...

 point72-hedge-fund-manager-steve-cohen-discloses-8-passive-stake-in-invivyd

-SEC Filing

 hc-wainwright--co-reiterates-buy-on-invivyd-maintains-5-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $5 price target.

 d-boral-capital-maintains-buy-on-invivyd-lowers-price-target-to-1

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:IVVD) with a Buy and lowers the price target from $3 to $1.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION